FindTrial
Sign In

Clinical study of esketamine hydrochloride combined with a targeted infusion of remifentanil in patients requiring awake intubation

Clinical study of esketamine hydrochloride combined with a targeted infusion of remifentanil in patients requiring awake intubation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076201
Enrollment
Unknown
Registered
2023-09-27
Start date
2023-09-30
Completion date
Unknown
Last updated
2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

difficult airway

Interventions

Group E:esketamine+ Rifentanil
Group D:Dexmedetomidine + Rifentanil

Sponsors

Luan Hospital of Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Our elective general anesthesia was evaluated in surgical patients requiring awake tracheal intubation, ASA class I-II, both sexes, age 18-64 years, BMI 18-32 kg/m2.

Exclusion criteria

Exclusion criteria: Central nervous system or psychiatric disorders, abnormal coagulation, difficulty with verbal communication, inability to cooperate, history of dexmedetomidine or esketamine hydrochloride allergy

Design outcomes

Primary

MeasureTime frame
Blood pressure;Ramsay sedation score;heart rate;blood oxygen saturation;respiratory rate;Postoperative follow-up;—

Secondary

MeasureTime frame
intubation reaction;Intubation time;First-time intubation success rate;—

Countries

China

Contacts

Public ContactRenhu Li

Luan Hospital of Anhui Medical University

lirenhu2008@163.com+86 139 6624 1616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026